Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Non-Current Assets for 5 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • Quarterly Non-Current Assets rose 466.42% to $1.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Sep 2025, up 42.93% year-over-year, with the annual reading at $148537.0 for FY2024, 49.75% down from the prior year.
  • Non-Current Assets for Q3 2025 was $1.1 million at Inhibikase Therapeutics, up from $58605.0 in the prior quarter.
  • The five-year high for Non-Current Assets was $1.1 million in Q3 2025, with the low at $2783.0 in Q1 2021.
  • Average Non-Current Assets over 5 years is $318834.6, with a median of $260264.0 recorded in 2024.
  • The sharpest move saw Non-Current Assets skyrocketed 743.87% in 2023, then plummeted 73.84% in 2025.
  • Over 5 years, Non-Current Assets stood at $2783.0 in 2021, then soared by 20208.12% to $565175.0 in 2022, then plummeted by 47.7% to $295599.0 in 2023, then crashed by 49.75% to $148537.0 in 2024, then soared by 612.22% to $1.1 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $1.1 million, $58605.0, and $116564.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.